I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail to a envelope addressed to:

PATENT Attorney Docket No.: 018781-006810US

RECEIVED

AUG 2 2 2002

COPY OF PAPERS ORIGINALLY FILED TECH CENTER 1600/2900

P#9

Assistant Commissioner for Paten Washington, D.C. 20231

on 7/8/02

TOWNSEND and FOWNSEND and CREW LLP

I REVOR / WIN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Scott POWERS et al.

Application No.: 10/041,030

Filed: December 28, 2001

For: DIAGNOSIS AND TREATMENT OF CANCER USING MAMMALIAN PELLINO POLYPEPTIDES AND POLYNUCLEOTIDES

Assistant Commissioner for Patents Washington, D.C. 20231

Examiner: To Be Assigned

Art Unit: 3736

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR §1.97 and

§1.98

RECEIVED

JUL 17 2002

TECHNOLOGY CENTER R3700

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. The sequence listing for reference A (2534 pages) has not been enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Scott POWERS et al. Application No.: 10/041,030

Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Jean M. Lockyer, Ph.D.

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: 415-576-0200 Fax: 415-576-0300

JML:trk

SF 1363073 v1

COPY OF PAPERS ORIGINALLY FILED

PTO/SB/08B (10-01) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE r the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute (orm 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known 10/041,030 **Application Number Filing Date** December 28, 2001 **First Named Inventor** Powers, Scott AUG 2 2 Art Unit 3736 **Examiner Name**

(use as many sheets as necessary)

To Be Assigned Sheet of 018781-006810US Attorney Docket Number

TECH CENTER 1600/2900

2002

U.S. PATENT DOCUMENTS						
		Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	
Examiner	Cite No.1	Number Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	

			FO	REIGN PA	TENT DOCUME	NTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or	Pages, Columns, Lines,		
		Country Code ³	Number ⁴	Kind Code ⁸ (If known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Τ°
	Α	EP	1 074 617	A2	07-28-2000			

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
	В	GROβHANS, J. et al., "Oligomerisation of tube and pelle leads to nuclear localisation of dorsal," Mechanisms of Development, 1999, pp. 127-138, Vol. 81.			

RECEIVED

JUL 1 7 2002

TECHNOLOGY CENTER R3700

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. SF 1363073 v1



¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.